Due to the risk of neurotoxicity from targeting a brain-expressed antigen, GRM4 is better suited for CAR-NK therapy, which has demonstrated a superior safety profile with minimal rates of severe CRS and ICANS in clinical studies (36, 37). This evidence concerns the gene GRM4 and congenital rubella syndrome.